AMD Awareness

Stem cells for dry AMD with GA show promise in early study

August 14, 2020

Subretinal transplantation of human embryonic stem cells (hESC)-derived retinal pigment epithelial (RPE) cells in patients with AMD and geographic atrophy (GA) appears well tolerated, according to date presented during ARVO 2020.

AMD, DED most common retinal conditions in the United States

August 13, 2020

The number of patients with retinal diseases is steadily increasing in the United States, according to a retrospective study presented during ARVO 2020.

Vision-related quality of life: Impacts of advanced AMD

August 01, 2020

Why progression to advanced disease may have a more dramatic impact on patients with neovascular AMD compared with those with central geographic atrophy.

ASRS 2020: Trial shows faricimab blocks Ang-2 and VEGF-A

July 27, 2020

Carl Danzig, MD, presented results of phase 2 Stairway Trial during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.

Evaluating the change in VA, CMT after early switch of anti-VEGF drugs

July 22, 2020

The study authors hypothesized that patients poorly responding to ranibizumab may have resulted from tachyphylaxis or tolerance to the drug and regarding the nonresponders, they speculated that VEGF-A may not have been the main cause of the neovascular growth.

Intravitreal gene therapy holds promise for novel wet AMD treatment

July 17, 2020

An in-office intravitreal therapy delivering a gene for aflibercept expression continues to demonstrate encouraging safety, tolerability, and efficacy in a phase 1 study of patients with neovascular age-related macular degeneration who require frequent injections to control their disease.